Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Compugen Ltd (CGEN)

Compugen Ltd (CGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,855
  • Shares Outstanding, K 86,625
  • Annual Sales, $ 33,460 K
  • Annual Income, $ -18,750 K
  • 60-Month Beta 2.63
  • Price/Sales 4.92
  • Price/Cash Flow N/A
  • Price/Book 2.68
Trade CGEN with:

Options Overview Details

View History
  • Implied Volatility 132.86% ( +5.43%)
  • Historical Volatility 63.88%
  • IV Percentile 27%
  • IV Rank 7.94%
  • IV High 1,177.03% on 12/14/23
  • IV Low 42.79% on 01/19/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 409
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 8,662
  • Open Int (30-Day) 8,624

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8301 +3.82%
on 04/18/24
2.7500 -30.91%
on 03/21/24
-0.6800 (-26.36%)
since 03/19/24
3-Month
1.7900 +6.15%
on 01/24/24
3.0301 -37.30%
on 03/08/24
-0.0400 (-2.06%)
since 01/19/24
52-Week
0.5300 +258.49%
on 11/13/23
3.0301 -37.30%
on 03/08/24
+1.2603 (+197.01%)
since 04/19/23

Most Recent Stories

More News
5 Growth Stocks Under $10 to Scoop Up Now

Investment in penny stocks can be a risky proposition. However, here are 5 stocks that could have major upside potential, according to Wall Street analysts.

CGEN : 1.9000 (+1.06%)
QCOM : 157.63 (-2.36%)
GSAT : 1.2700 (+1.60%)
BITF : 1.9200 (+1.59%)
INDI : 5.36 (-3.25%)
KOS : 5.98 (-1.32%)
Compugen to Present at Single Cell Genomics 2023 Meeting

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9000 (+1.06%)
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9000 (+1.06%)
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9000 (+1.06%)
Compugen Reports Second Quarter 2023 Results

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and...

CGEN : 1.9000 (+1.06%)
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9000 (+1.06%)
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9000 (+1.06%)
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9000 (+1.06%)
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...

CGEN : 1.9000 (+1.06%)
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer

COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate 22% (2/9)...

CGEN : 1.9000 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas...

See More

Key Turning Points

3rd Resistance Point 2.1033
2nd Resistance Point 2.0367
1st Resistance Point 1.9683
Last Price 1.9000
1st Support Level 1.8333
2nd Support Level 1.7667
3rd Support Level 1.6983

See More

52-Week High 3.0301
Fibonacci 61.8% 2.0751
Last Price 1.9000
Fibonacci 50% 1.7801
Fibonacci 38.2% 1.4850
52-Week Low 0.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar